| Nov 6 |
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
|
| Nov 1 |
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
|
| Oct 31 |
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
|
| Oct 28 |
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
|
| Oct 3 |
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
|
| Sep 17 |
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
|
| Sep 9 |
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
|
| Sep 5 |
Lisata jumps on FDA orphan drug status for liver cancer drug
|
| Sep 5 |
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
|
| Aug 22 |
Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?
|
